全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

为什么选择我们？ >>
- 开源期刊
- 同行审议
- 快速出刊
- 终身存储
- 免费检索
- 免费推广
- 更多...
- 搜索引擎

Breast Cancer Research

ISSN Print: 1465-5411

ISSN Online:

主页: http://breast-cancer-research.com

分享:




Go

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis

Bhumsuk Keam, Seock-Ah Im, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh, Jee Kim, Se-Hoon Lee, Wonshik Han, Dong-Wan Kim, Tae-You Kim, In Park, Dong-Young Noh, Dae Heo, Yung-Jue Bang

Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer

Bethany N Hannafon, Paola Sebastiani, Antonio de las Morenas, Jining Lu, Carol L Rosenberg

Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy

Yvonne Hui-Fang Teng, Wai-Jin Tan, Aye-Aye Thike, Poh-Yian Cheok, Gary Man-Kit Tse, Nan-Soon Wong, George Wai-Cheong Yip, Boon-Huat Bay, Puay-Hoon Tan

Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study

Sang Oh, Cheol-Young Park, Eun Lee, Yeong Yoon, Eon Lee, Sang Park, Yuil Kim, Nak Sung, Young Yun, Keun Lee, Han Kang, Youngmee Kwon, Jungsil Ro

DNA repair and breast cancer: therapeutic opportunities

DP Silver

The phosphatidylinositol-3 kinase/mTOR pathway: new agents

CL Arteaga

Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?

R Plummer

Molecular classification of triple-negative tumors

A Prat, CM Perou

Mutation screening of RAD51C in male breast cancer patients

Valentina Silvestri, Piera Rizzolo, Mario Falchetti, Ines Zanna, Giovanna Masala, Domenico Palli, Laura Ottini

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib

Cristina Oliveras-Ferraros, Sílvia Cufí, Tamara Sauri-Nadal, Sonia Barco, Bego？a Martin-Castillo, Alejandro Vazquez-Martin, Javier A Menendez

Oestrogen receptor status predicts for local recurrence following wide local excision for breast tumours

JWK Lee, CTM Ong, EY Tan, MYP Chan

Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy

L Manso, E Ciruelos, M Codes, J De la Haba, A Galan, J Baena, A Jaen, M Gil, A Murias, I Blancas, E Gonzalez, D Perez, JL Bayo, J Mel, E Garcia-Martinez, R Cubedo, J Salvador

Nestin and collagen triple helix repeat containing 1 in breast cancer progression

G Kharaishvili, D Simkova, M Cizkova, K Bouchalova, G Mgebrishvili, Z Kolar, J Bouchal

Clinical features and prognosis of tubular breast cancer

M Izquierdo Sanz, F Tresserra Casas, G Nacho Rodríguez, R Fabregas Xaurado, M Cusido Gimferrer, C Ara Perez, S Baulies Caballero

Translational breast cancer research in luminal breast cancer

M Dowsett

Molecular heterogeneity of luminal breast cancer

S Loi

Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer

J Baselga, F Costa, H Gomez, C Hudis, B Rapoport, H Roche, LS Schwartzberg, O Petrenciuc, M Shan, WJ Gradishar

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2

Anna Mulligan, Fergus J Couch, Daniel Barrowdale, Susan M Domchek, Diana Eccles, Heli Nevanlinna, Susan J Ramus, Mark Robson, Mark Sherman, Amanda B Spurdle, Barbara Wappenschmidt, Andrew Lee, Lesley McGuffog, Sue Healey, Olga M Sinilnikova, Ramunas Janavicius, Thomas vO Hansen, Finn C Nielsen, Bent Ejlertsen, Ana Osorio, Iván Mu？oz-Repeto, Mercedes Durán, Javier Godino, Maroulio Pertesi, Javier Benítez, Paolo Peterlongo, Siranoush Manoukian, Bernard Peissel, Daniela Zaffaroni, Elisa Cattaneo

Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients

Hitesh N Appaiah, Chirayu P Goswami, Lida A Mina, Sunil Badve, George W Sledge, Yunlong Liu, Harikrishna Nakshatri

Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer

Yuqing Li, Yi Li, Sara Wedrén, Guoliang Li, Tze Howe Charn, Kartiki Vasant Desai, Carine Bonnard, Kamila Czene, Keith Humphreys, Hatef Darabi, Kristjana Einarsdóttir, Tuomas Heikkinen, Kristiina Aittom？ki, Carl Blomqvist, Kee Seng Chia, Heli Nevanlinna, Per Hall, Edison T Liu, Jianjun Liu

Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors

Jun J Mao, H Irene Su, Rui Feng, Michelle L Donelson, Richard Aplenc, Timothy R Rebbeck, Frank Stanczyk, Angela DeMichele

Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study

Florence Le Calvez-Kelm, Fabienne Lesueur, Francesca Damiola, Maxime Vallée, Catherine Voegele, Davit Babikyan, Geoffroy Durand, Nathalie Forey, Sandrine McKay-Chopin, Nivonirina Robinot, Tù Nguyen-Dumont, Alun Thomas, Graham B Byrnes, Breast Cancer Family Registry, John L Hopper, Melissa C Southey, Irene L Andrulis, Esther M John, Sean V Tavtigian

Proliferation-associated POU4F2/Brn-3b transcription factor expression is regulated by oestrogen through ERα and growth factors via MAPK pathway

Samir Ounzain, Samantha Bowen, Chandrakant Patel, Rieko Fujita, Richard J Heads, Vishwanie S Budhram-Mahadeo

Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer

Lisa M Arendt, Debra E Rugowski, Tara A Grafwallner-Huseth, Maria Jose Garcia-Barchino, Hallgeir Rui, Linda A Schuler

A local basis for progesterone action during mammary tumorigenesis - no longer RANK and file

Whitney K Petrie, Russell C Hovey

Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo

Mark Barok, Minna Tanner, Katri K？ninki, Jorma Isola

α-Tocopheryloxyacetic acid: a novel chemotherapeutic that stimulates the antitumor immune response

Tobias Hahn, Bhumasamudram Jagadish, Eugene A Mash, Kendra Garrison, Emmanuel T Akporiaye

Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth

Li Xu Yan, Qi Nian Wu, Yan Zhang, Yang Yang Li, Ding Zhun Liao, Jing Hui Hou, Jia Fu, Mu Sheng Zeng, Jing Ping Yun, Qiu Liang Wu, Yi Xin Zeng, Jian Yong Shao

α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73

Richa Tiwary, Weiping Yu, Bob G Sanders, Kimberly Kline

Do aromatase inhibitors have adverse effects on cognitive function?

Kelly Phillips, Karin Ribi, Richard Fisher

Arbitration cancers: analysis from two screening rounds for the Coventry, Solihull and Warwickshire screening service

S Garnett

Early identification of substandard breast screening performers

L Dong, Y Chen, AG Gale

Large-bore vacuum-assisted biopsy of axillary lymphadenopathy

ND Forester, P Burrows, A Jack, A-M Wason

Comparison of mammographic findings and need for ultrasound and biopsy in women undergoing wide local excision and either intraoperative radiotherapy or external beam whole breast irradiation

A Romsauerova, J Dewar, D Brown, A Evans

Mammographic density and breast cancer risk: current understanding and future prospects

Norman F Boyd, Lisa J Martin, Martin J Yaffe, Salomon Minkin

Clinical relevance and biology of circulating tumor cells

Natalia Bednarz-Knoll, Catherine Alix-Panabières, Klaus Pantel

A clinically relevant gene signature in triple negative and basal-like breast cancer

Achim Rody, Thomas Karn, Cornelia Liedtke, Lajos Pusztai, Eugen Ruckhaeberle, Lars Hanker, Regine Gaetje, Christine Solbach, Andre Ahr, Dirk Metzler, Marcus Schmidt, Volkmar Müller, Uwe Holtrich, Manfred Kaufmann

Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer

Rachel C Jankowitz, Kristine Cooper, Mark G Erlander, Xiao-Jun Ma, Nicole C Kesty, Hongying Li, Mamatha Chivukula, Adam Brufsky

Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression

Olafur A Stefansson, Jon G Jonasson, Kristrun Olafsdottir, Hordur Bjarnason, Oskar Th Johannsson, Sigridur K Bodvarsdottir, Sigridur Valgeirsdottir, Jorunn E Eyfjord

Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10

Petra EA Huijts, Minka van Dongen, Moniek CM de Goeij, Adrian J van Moolenbroek, Freek Blanken, Maaike PG Vreeswijk, Esther M de Kruijf, Wilma E Mesker, Erik W van Zwet, Rob AEM Tollenaar, Vincent THBM Smit, Christi J van Asperen, Peter Devilee

Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles

William Jacot, Evelyne Lopez-Crapez, Simon Thezenas, Romain Senal, Frédéric Fina, Frédéric Bibeau, Gilles Romieu, Pierre-Jean Lamy

Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer

Priscilla A Furth, Rebecca E Nakles, Sarah Millman, Edgar S Diaz-Cruz, M Carla Cabrera

Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67

Shinichiro Kashiwagi, Masakazu Yashiro, Tsutomu Takashima, Naoki Aomatsu, Katsumi Ikeda, Yoshinari Ogawa, Tetsuro Ishikawa, Kosei Hirakawa

Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion

Narendra V Sankpal, John D Mayfield, Mike W Willman, Timothy P Fleming, William E Gillanders

Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases

Barbara Adamo, Allison M Deal, Emily Burrows, Joseph Geradts, Erika Hamilton, Kimberly L Blackwell, Chad Livasy, Karen Fritchie, Aleix Prat, J Harrell, Matthew G Ewend, Lisa A Carey, C Miller, Carey K Anders

Functional magnetic resonance: biomarkers of response in breast cancer

Elizabeth AM O'Flynn, Nandita M deSouza

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen

Stephen B Fox, Daniele Generali, Alfredo Berruti, Maria P Brizzi, Leticia Campo, Simone Bonardi, Alessandra Bersiga, Giovanni Allevi, Manuela Milani, Sergio Aguggini, Teresa Mele, Luigi Dogliotti, Alberto Bottini, Adrian L Harris

The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients

Timothy J Molloy, Astrid J Bosma, Lars O Baumbusch, Marit Synnestvedt, Elin Borgen, Hege Russnes, Ellen Schlichting, Laura J van't Veer, Bj？rn Naume

Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients

Galatea Kallergi, Maria A Papadaki, Eleni Politaki, Dimitris Mavroudis, Vassilis Georgoulias, Sophia Agelaki

Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse

Emmanouil Saloustros, Maria Perraki, Stella Apostolaki, Galatea Kallergi, Alexandros Xyrafas, Kostas Kalbakis, Sophia Agelaki, Antonia Kalykaki, Vassilis Georgoulias, Dimitris Mavroudis

Go




©2008-2020 OALib, Inc | Public user content licensed CC-BY 4.0 unless otherwise specified. OALib ISSN Online: 2333-9721 OALib ISSN Print: 2333-9705